Welcome to Telomium, a biotechnology company focused on immunotherapy




Telomium develops vaccines of a completely new class in the pharmacopoeia: ribonucleoproteins, which have a unique ability to orchestrate the break of immune tolerance against pathogenic tissues like cancer.

The prominent ability of ribonucleoproteins to bypass immune tolerance against the self provides a decisive advantage for cancer immunotherapy.


Our lead product TLVX01 is a first-in-class ribonucleoprotein based on telomerase. It has the ideal formulation to trigger an autoimmune reaction targeted against almost any type of cancer...  read more.